Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 16/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 16/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828179 | 0.86 | LMNA (0.57) | MEN1KMT2ALMNASCN9A | |
| SCHEMBL2228194 | 0.86 | LMNA (0.57) | MEN1KMT2ALMNASCN9A | |
| SCHEMBL29809574 | 0.85 | ECE1 (0.56) | MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL10331461 | 0.85 | ECE1 (0.56) | MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL10407750 | 0.83 | TAS1R3 (0.68) | TAS1R3TAS1R1 | |
| SCHEMBL6241209 | 0.83 | TAS1R3 (0.68) | TAS1R3TAS1R1 | |
| SCHEMBL19588666 | 0.83 | MEN1 (0.52) | MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL6860349 | 0.82 | ECE1 (0.62) | MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL22460628 | 0.82 | TAS1R3 (0.55) | TAS1R3TAS1R1MEN1KMT2ALMNA | |
| SCHEMBL6860711 | 0.82 | KMT2A (0.51) | MEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| EP-2528898-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | Kareus Therapeutics SA (FR) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | TAS1R3 4701/4885TAS1R1 4784/4885MEN1 4437/4885 |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | TAS1R3 4701/4885TAS1R1 4784/4885MEN1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.